Get the Stockscreener App
108.61
10.04%
-12.12
Pre-market:
108.99
0.38
+0.35%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $108.61, with a volume of 38.11M.
It is down -10.04% in the last 24 hours and down -13.25% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$120.73
Open:
$107.53
24h Volume:
38.11M
Relative Volume:
5.67
Market Cap:
$188.86B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
13.62
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-12.08%
1M Performance:
-13.25%
6M Performance:
-13.62%
1Y Performance:
-7.79%
1-Day Range:
$105.78
$114.00
1-Week Range:
$105.78
$123.49
52-Week Range:
$105.78
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.61 | 209.93B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
358.67 | 138.80B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
91.29 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
101.34 | 128.57B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.44 | 49.41B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Stock Suffers Worst Drop In More Than 20 Years - Eudaimonia and Co
Abbott Laboratories Share Price Falls 8% After Revenue Miss | Stock Market Today - Samco
Abbott Stock Suffers Worst Drop in More Than 20 Years - The Wall Street Journal
Abbott has mixed Q4 results, but medtech sales up 12.3% - MassDevice
Abbott Laboratories Earnings Call: Devices Offset Nutrition Drag - TipRanks
Traders Purchase High Volume of Put Options on Abbott Laboratories (NYSE:ABT) - MarketBeat
Abbott misses Q4 expectations - BioWorld MedTech
Stock Movers: Carvana, Abbott, Intel - Bloomberg.com
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness - FinancialContent
Intel, GE Aerospace, Moderna, Abbott, Mobileye, McCormick, and More Stock Movers - Barron's
Abbott Falls Short in 4th Quarter Earnings - Medical Device and Diagnostic industry
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Abbott Laboratories (ABT) Q4 2025 Earnings Call Highlights: Navi - GuruFocus
Abbott Dives 7% On Quarterly Upset As Exact Close Looms - Investor's Business Daily
Abbott Sales Miss Estimates on Nutrition Unit Struggles - Bloomberg
Abbott Laboratories (ABT) Q4 2025 Earnings Call Highlights: Navigating Market Challenges with ... - Yahoo Finance
Abbott stock slumps. The nutrition business is a drag on earnings. - MSN
Russell 2000 Extends Records, Meta Jumps 5%Abbott Laboratories (NYSE:ABT), Arista Networks (NYSE:ANET) - Benzinga
Abbott’s medtech sales climbed in Q4 thanks to strength of heart devices - Cardiovascular Business
Abbott Forecasts Lower Q1 Profit as Nutrition Discounts Hit Resu - GuruFocus
Abbott Stock Drops on Slumping Sales of Baby Formula and Nutrition Shakes - The Wall Street Journal
Abbott Forecasts Lower Q1 Profit as Nutrition Discounts Hit Results - Yahoo Finance
Abbott Laboratories Raised Prices, Prompting Sales Slump - The Wall Street Journal
Abbott Laboratories (ABT) Eyes Growth with Strategic Moves and P - GuruFocus
Abbott Labs dips 9% as Q4 revenue misses forecasts - breakingthenews.net
Abbott Broadens Cardiology And Oncology Reach As Valuation Questions Persist - simplywall.st
Abbott’s stock falls by nearly 11% following Q4 sales miss - Yahoo Finance
Why Abbott Laboratories (ABT) Shares Are Sliding Today - Yahoo Finance
Abbott (ABT) Shares Decline Amid Market Activity - GuruFocus
Abbott posts Q4 sales below expectations - MedTech Dive
Abbott Laboratories Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Abbott slumps over 8% after missing Q4 revenue targets, lower Q1 forecast - Mint
Abbott Laboratories Q4 Earnings Call Highlights - Yahoo Finance
Abbott misses fourth quarter expectations amid slump in nutrition segment - chicagobusiness.com
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results - Benzinga
Earnings: Highlights of Abbott Laboratories’ (ABT) Q4 2025 report - AlphaStreet
Abbott (ABT) Stock Declines Over 7% to $111.73 - GuruFocus
Abbott Stock Slid As 2025 Outlook Fell Short - Finimize
Abbott Labs Faces Setback with Q4 Revenue Miss and Cautious Guid - GuruFocus
Abbott Q4 2025 presentation slides: Revenue miss overshadows EPS growth - Investing.com
Intel, GE Aerospace, Moderna, Abbott, Arista, Mobileye, McCormick, and More Movers - Barron's
Abbott (ABT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Abbott Stock Slides 7% After Q4 Results And 2026 Outlook Disappoint Investors - Nasdaq
Abbott Laboratories (ABT) Stock: Q4 Revenue Hits $11.46B but Shares Drop 7.35% - CoinCentral
Stock Movers: Corcept Therapeutic, Abbott Labs, Arista Networks - Bloomberg.com
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat - The Chronicle-Journal
ABT Plans New Product Launches Amid Forecasted Nutrition Sales C - GuruFocus
Earnings call transcript: Abbott Labs Q4 2025 results miss revenue forecast - Investing.com
AI for investors - MLQ.ai
Abbott shares slide after Q4 revenue comes in short, outlook disappoints - MSN
Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls - Yahoo Finance
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):